Calla Lily Clinical Care and Merck have entered a strategic collaboration to support the continued development of Callavid®, a novel platform for intravaginal drug delivery. This partnership marks the first industry collaboration for the Callavid technology, which aims to address significant challenges in the self-administration of vaginal therapeutics.
The Callavid device is designed to mitigate patient anxiety associated with vaginal drug administration, particularly regarding positioning, dosing accuracy, and leakage. Its innovative, leak-resistant design allows for hygienic insertion and reliable drug absorption, enhancing the overall patient experience. The device is particularly relevant for therapeutics in fertility treatments, oncology, and hormone therapies.
Thang Vo-Ta, Co-founder and CEO of Calla Lily Clinical Care, emphasized the importance of this collaboration, stating that it represents a significant step toward addressing unmet needs in women’s health. The partnership with Merck is expected to facilitate the translation of Callavid’s technology into impactful clinical applications. As the company seeks to broaden its therapeutic reach, including indications for oncology and infectious diseases, this collaboration presents a strategic opportunity for pharmaceutical partners to leverage a differentiated drug delivery modality.
Open the full market picture for your next decision →
